Clinical impact of duloxetine treatment on sleep in patients with major depressive disorder

International Clinical Psychopharmacology

Volumn 23, Issue 6, 2008, Pages 317-324

  Brecht, Stephan ^a   Kajdasz, Daniel ^b   Ball, Susan ^b   Thase, Michael E ^c  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Dual reuptake inhibitor; Duloxetine; Major depressive disorder; Sleep

Indexed keywords

CHLORAL HYDRATE; DULOXETINE; VENLAFAXINE; ZOLPIDEM;

ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; DREAM; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HYPERSOMNIA; INSOMNIA; MAJOR DEPRESSION; META ANALYSIS; NARCOLEPSY; PARASOMNIA; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; SLEEP; SLEEP APNEA SYNDROME; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WAKEFULNESS;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; SLEEP; SLEEP DISORDERS; THIOPHENES; TREATMENT OUTCOME;

EID: 55849127457     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328306a987     Document Type: Article

References (29)

1. American Psychiatric Association (1994). The Diagnostic and Statistical Manual for Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press.
2. Argyropoulos SV, Hicks JA, Nash JR, Bell CJ, Rich AS, Nutt DJ, et al. (2003). Correlation of subjective and objective sleep measurements at different stages of the treatment of depression. Psychiatry Res 120:179-190.
3. Bech P, Kajdasz DK, Porsdal V (2006). Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder. Psychopharmacology doi: 10.1007/s00213-006-0505-1.
4. Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF (2005). Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psych Res 39:43-53.
5. Chalon S, Pereira A, Lainey E, et al. (2005). Comparative effects of duloxetine and desipramine on sleep EEG in healthy subjects. Psychopharmacology 177:357-365.
6. Cleeland CS, Ryan KM (1994). Pain assessment: global use of the brief pain inventory. Ann Acad Med 23:129-138.
7. Culpepper L (2006). Secondary insomnia in the primary care setting: review of diagnosis, treatment, and management. Curr Med Res Opin 22:1257-1268.
8. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA (2002a). Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 63:308-315.
9. Detke MJ, Lu L, Goldstein DJ, McNamara RK, Demitrack MA (2002b). Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psych Res 36:383-390.
10. Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I (2004). Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychophar macol 14:457-470.
11. Edinger JD, Fins AI, Glenn DM, Sullivan RJ, Bastian LA, Marsh GR, et al. (2000). Insomnia and the eye of the beholder: are there clinical markers of objective sleep disturbance among adults with and without insomnia complaints? J Consult Clin Psychology 68:586-593.
12. Gardner DM, MacKinnon N, Langille DB, Andreou P (2007). A comparison of factors use by physicians and patients in the selection of antidepressant agents. Psychiatr Serv 58:34-40.
13. Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA (2002). Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 63:225-231.
14. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA (2004). Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 24:389-399.
15. Guy W (1976). The clinician global severity and impression scales. ECDEU Assessment Manual for Psychopharmacology (76-338). Rockville, MD: US Dept Health, Education, and Welfare; pp. 218-222.
16. Hamilton M (1967). Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-296.
17. Hudson JI, Pope HG, Sullivan LE, Waternaux CM, Keck PE, Broughton RJ (1992). Good sleep, bad sleep: a meta-analysis of polysomnographic measures in insomnia, depression, and narcolepsy. Biol Psychiatry 32:958-975.
18. Kluge M, Schlusser P, Steiger A (2007). Duloxetine increases stage 3 sleep and suppresses rapid eye movement (REM) sleep in patients with major depression. European Psychopharmacol doi:10.1016/j.euro-neuro.2007.01. 006.
19. Lam RW (2006). Sleep disturbances and depression: a challenge for antidepressants. Int Clin Psychopharmacol 2:S25-S29.
20. Manber R, Blasey C, Markowitz AB, Thase ME, Rush AJ, Dowling F, et al. (2005). Assessing insomnia severity in depression: a comparison of depression rating scale and sleep diaries. J Psychiatr Res 39:481-488.
21. Montgomery SA, Asberg MA (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
22. Perahia DGS, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ (2006). Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry 21:367-378.
23. Nemeroff CB, Schatzberg AF, Goldstein DJ, Detke MJ, Mallinckrodt C, Lu Y, et al. (2002). Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 36:106-132.
24. Raskin J, Wiltse CG, Siegal A, Sheikh J, Xu J, Dinkel JJ, et al. (2007). Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 164:900-909.
25. Ruhe HG, Dekker JJ, Peen J, Holman R, de Jonghe F (2005). Clinical use of the Hamilton Depression Rating Scale: is increased efficiency possible? A post hoc comparison of Hamilton Rating Scale, Maier and Bech subscales, Clinical Global Impression, and Symptom Checklist-90 scores. Compr Psychiatry 46:417-427.
26. Sanchez C, Brennum LT, Storustovu S, Kreilgard M, Mork A (2007). Depression and poor sleep: the effect of monoaminergic antidepressants in a pre-clinical model in rats. Pharmacol, Biochem, Behavior 86:468-476.
27. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Javas J, Weiller E, et al. (1998). The MINI International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured psychiatric interview for DSM-IV. J Clin Psychiatry 59 (Suppl 20):34-57.
28. Wilson S, Argyropoulos S (2005). Antidepressants and sleep: a qualitative review of the literature. Drugs 65:927-947.
29. Zimmerman M, Chelminski I, Posternak MA (2004). A review of studies of the Hamilton Depression Rating Scale in healthy controls: implications for the definition of remission in treatment studies of depression. J Nerv Mental Dis 192:595-601.